The surgical treatment of hepatic metastases in colorectal carcinoma;Chirurgische therapie von lebermetastasen beim kolorektalen karzinom

Deutsches Arzteblatt

Volumn 107, Issue 19, 2010, Pages 335-342

  Neumann, Ulf Peter ^a,b   Seehofer, Daniel ^a   Neuhaus, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLIC ACID; IRINOTECAN; OXALIPLATIN;

ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; FATTY LIVER; HUMAN; INOPERABLE CANCER; LIVER DISEASE; LIVER METASTASIS; LIVER RESECTION; LIVER SINUSOIDAL OBSTRUCTION; MEDLINE; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PORTAL VEIN; PREOPERATIVE TREATMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; REOPERATION; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EMBOLIZATION, THERAPEUTIC; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOADJUVANT THERAPY; PATIENT CARE TEAM; PORTAL VEIN; PROGNOSIS; TUMOR BURDEN;

EID: 77953307543     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2010.0335     Document Type: Review

References (81)

1. Scheele J, Stangl R, Altendorf-Hofmann A: Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990; 77: 1241-6.
2. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-18; discussion 318-21. (Pubitemid 30191861)
3. Jonas S, Thelen A, Benckert C, et al. Extended resections of liver metastases from colorectal cancer. World J Surg 2007; 31: 511-21. (Pubitemid 46356071)
4. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16: 1311-9. (Pubitemid 41158476)
5. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM: Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-47; discussion 447-50. (Pubitemid 39121338)
6. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 2002; 235: 759-66.
7. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-80.
8. Iwatsuki S, Esquivel CO, Gordon RD, Starzl TE: Liver resection for metastatic colorectal cancer. Surgery 1986; 100: 804-10. (Pubitemid 16008854)
9. Nordlinger B, Guiguet M, Vaillant JC, et al.: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996; 77: 1254-62.
10. Elias D, Cavalcanti A, Sabourin JC, Pignon JP, Ducreux M, Lasser P: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998; 69: 88-93. (Pubitemid 28515966)
11. Pawlik TM, Scoggins CR, Zorzi D, et al.: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005; 241: 715-22, discussion 722-4. (Pubitemid 40604917)
12. Thelen A, Jonas S, Benckert C, et al.: Repeat liver resection for recurrent liver metastases from colorectal cancer. Eur J Surg Oncol 2007; 33: 324-8. (Pubitemid 46356071)
13. Bismuth H, Adam R, Levi F, et al.: Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-20; discussion 520-2. (Pubitemid 26337559)
14. Adam R, Aloia T, Levi F, et al.: Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593-602. (Pubitemid 350035318)
15. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-72. (Pubitemid 46622116)
16. Azoulay D, Castaing D, Smail A, et al.: Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000; 231: 480-6. (Pubitemid 30185853)
17. Adam R, Laurent A, Azoulay D, Castaing D, Bismuth H: Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-85.
18. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C: Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004; 39: 689-97. (Pubitemid 39425962)
19. Abdalla EK, Vauthey JN: Colorectal metastases: resect or ablate? Ann Surg Oncol 2006; 13: 602-3.
20. Kemeny NE, Gonen M: Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-5.
21. Lorenz M, Muller HH, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228: 756-62.
22. Portier G, Elias D, Bouche O, et al.: Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-82.
23. Mitry E, Fields AL, Bleiberg H, et al.: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-11.
24. Parks R, Gonen M, Kemeny N, et al.: Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204: 753-61.
25. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-16.
26. Schmiegel W, Pox C, Reinacher-Schick A, et al.: S3-Leitlinie "Kolorektales Karzinom" Ergebnisse evidenzbasierter Konsensuskonferenzen am 6./7. Februar 2004 und am 8./9. Juni 2007 (für die Themenkomplexe IV, VI und VII) S3-Guideline "Colorectal Cancer" 2004/2008. Z Gastroenterol 2008; 46: 1-73.
27. Andreoni B, Chiappa A, Bertani E, et al.: Surgical outcomes for colon and rectal cancer over a decade: results from a consecutive monocentric experience in 902 unselected patients. World J Surg Oncol 2007; 5: 73.
28. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51.
29. Schmiegel W, Pox C, Arnold D, Porschen R, Rödel C, Reinacher- Schick A: Clinical practice guideline: Colorectal carcinoma - The managment of polyps, (neo)adjuvant therapie, and the treatment of metastases [Klinische Leitlinie Kolorektales Karzinom - Polypenmanagement, (neo)adjuvante Therapie, Therapie im metastasierten Stadium]. Dtsch Arztebl Int 2009; 106: 843-8.
30. Adson MA, Van Heerden JA: Major hepatic resections for metastatic colorectal cancer. Ann Surg 1980; 191: 576-83.
31. Jaeck D, Bachellier P, Guiguet M, et al.: Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84: 977-80.
32. Nordlinger B, Rougier P: Liver metastases from colorectal cancer: the turning point. J Clin Oncol 2002; 20: 1442-5.
33. Ringe B, Bechstein WO, Raab R, Meyer HJ, Pichlmayr R: [Liver resection in 157 patients with colorectal metastases]. Chirurg 1990; 61: 272-9.
34. Ekberg H, Tranberg KG, Andersson R, et al.: Determinants of survival in liver resection for colorectal secondaries. Br J Surg 1986; 73: 727-31.
35. Hagspiel KD, Neidl KF, Eichenberger AC, Weder W, Marincek B: Detection of liver metastases: comparison of superparamagnetic iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US. Radiology 1995; 196: 471-8.
36. Wildi SM, Gubler C, Hany T, et al.: Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound 2008; 36: 20-6.
37. Kong G, Jackson C, Koh DM, et al.: The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35: 1323-9.
38. Wiering B, Ruers TJ, Krabbe PF, Dekker HM, Oyen WJ: Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007; 14: 818-26.
39. Arulampalam TH, Francis DL, Visvikis D, Taylor I, Ell PJ: FDG-PET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004; 30: 286-91.
40. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-44.
41. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
42. Poston GJ: The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2005; 31: 325-30.
43. Seium Y, Stupp R, Ruhstaller T, et al.: Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. Ann Oncol 2005; 16: 762-6.
44. Bismuth H, Castaing D, Traynor O: Surgery for synchronous hepatic metastases of colorectal cancer. Scand J Gastroenterol Suppl 1988; 149: 144-9.
45. Elias D, Sideris L, Pocard M, et al.: Results of R0 resection for colorectal liver metastases associated with extrahepatic disease. Ann Surg Oncol 2004; 11: 274-80.
46. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-46.
47. Scheele J, Altendorf-Hofmann A, Grube T, Hohenberger W, Stangl R, Schmidt K: [Resection of colorectal liver metastases. What prognostic factors determine patient selection?]. Chirurg 2001; 72: 547-60.
48. Sugihara K, Hojo K, Moriya Y, Yamasaki S, Kosuge T, Takayama T: Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 1993; 80: 1032-5.
49. Iwatsuki S, Dvorchik I, Madariaga JR, et al.: Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 1999; 189: 291-9.
50. Pawlik TM, Vauthey JN: Surgical margins during hepatic surgery for colorectal liver metastases: complete resection not millimeters defines outcome. Ann Surg Oncol 2008; 15: 677-9.
51. Wray CJ, Lowy AM, Matthews JB, et al.: Intraoperative margin re-resection for colorectal liver metastases. J Surg Educ 2007; 64: 150-7.
52. Huguet C, Bona S, Nordlinger B, et al.: Repeat hepatic resection for primary and metastatic carcinoma of the liver. Surg Gynecol Obstet 1990; 171: 398-402.
53. Nordlinger B, Vaillant JC: Repeat resections for recurrent colorectal liver metastases. Cancer Treat Res 1994; 69: 57-61.
54. Douillard JY: Irinotecan and high-dose fluorouracil/leucovorin for metastatic colorectal cancer. Oncology (Williston Park) 2000; 14(12 Suppl 14): 51-5.
55. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-57; discussion 657-8.
56. Rubbia-Brandt L, Audard V, Sartoretti P, et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-6.
57. Rubbia-Brandt L, Giostra E, Brezault C, et al.: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 2007; 18: 299-304.
58. Karoui M, Penna C, Amin-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006; 243: 1-7.
59. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK: Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 2007; 94: 274-86.
60. Kokudo N, Tada K, Seki M, et al.: Proliferative activity of intrahepatic colorectal metastases after preoperative hemihepatic portal vein embolization. Hepatology 2001; 34: 267-72.
61. Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002; 137: 675-80; discussion 680-1.
62. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P: Preoperative right portal vein embolization in patients with metastatic liver disease. Metastatic liver volumes after RPVE. Acta Radiol 2003; 44: 98-102.
63. Elias D, Ouellet JF, De Baere T, Lasser P, Roche A: Preoperative selective portal vein embolization before hepatectomy for liver metastases: long-term results and impact on survival. Surgery 2002; 131: 294-9.
64. Jaeck D, Bachellier P, Nakano H, et al.: One or two-stage hepatectomy combined with portal vein embolization for initially nonresectable colorectal liver metastases. Am J Surg 2003; 185: 221-9.
65. Togo S, Nagano Y, Masui H, et al.: Two-stage hepatectomy for multiple bilobular liver metastases from colorectal cancer. Hepatogastroenterology 2005; 52: 913-9.
66. Tanaka K, Shimada H, Matsuo K, Ueda M, Endo I, Togo S: Remnant liver regeneration after two-stage hepatectomy for multiple bilobar colorectal metastases. Eur J Surg Oncol 2007; 33: 329-35.
67. Jaeck D, Oussoultzoglou E, Rosso E, Greget M, Weber JC, Bachellier P: A two-stage hepatectomy procedure combined with portal vein embolization to achieve curative resection for initially unresectable multiple and bilobar colorectal liver metastases. Ann Surg 2004; 240: 1037-49; discussion 1049-51.
68. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239: 818-25; discussion 825-7.
69. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-48.
70. Minagawa M, Makuuchi M, Torzilli G, et al.: Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 2000; 231: 487-99.
71. Cady B, Jenkins RL, Steele GD, Jr., et al.: Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227: 566-71.
72. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995; 19: 59-71.
73. Masi G, Cupini S, Marcucci L, et al.: Treatment with 5-fluorouracil/ folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. Ann Surg Oncol 2006; 13: 58-65.
74. Giacchetti S, Itzhaki M, Gruia G, et al.: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663-9.
75. Pozzo C, Basso M, Cassano A, et al.: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-9.
76. De La Cámara J, Rodriguez J, Rotellar F, et al.: Triplet therapy with oxaliplatin, irinotecan, 5-fluorouracil and folinic acid within a combined modality approach in patients with liver metastases from colorectal cancer. J Clin Oncol 2004; 22 (Suppl. 14s) (Abstract 3593).
77. Quenet F, Nordlinger B, Rivoire M, et al.: Resection of previously unresectable liver metastases from colorectal cancer (LMCRC) after chemotherapy (CT) with CPT-11/L-OHP/LV5FU (Folfirinox): A prospective phase II trial. J Clin Oncol 2004; 22 (Suppl. 14s): Abstract 3613.
78. Alberts SR, Horvath WL, Sternfeld WC, et al.: Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9.
79. Ho WM, Ma B, Mok T, et al.: Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group. Med Oncol 2005; 22: 303-12.
80. Folprecht G, Gruenberger T, Hartmann JT, et al.: Randomized multicenter study of cetuximab plus FOLFOX or plus FOLFIRI in neoadjuvant treatment of non-resectable colorectal liver metastases (CELIM-study). Ann Oncol 2008; 19 (Suppl. 8): viii 168.
81. Lygidakis NJ, Sgourakis G, Vlachos L, et al.: Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 2001; 48: 1685-91.